SYNGENE Syngene International Q2 FY25 results (Jul–Sep 2024) and concall
Syngene reported a broadly flat YoY performance for Q2 FY25, though strong sequential revenue growth of 13% signals a recovery phase. Management highlighted increased inquiries in Discovery Services as clients seek alternatives to China, while the Biologics segment prepares for a capacity boost in the second half. Despite a muted first half, the company maintains its full-year guidance, expecting momentum to build significantly in H2.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 891 |
| EBITDA | 245 |
| Net profit | 106 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
